RESUMEN
Context: Thyroid dysfunction is a common endocrine disorder. Lifestyle changes such as the use of complementary therapies namely yoga, regular physical activity, and proper diet may reduce the risk of endocrinal dysfunction and may help individuals to maintain a healthy weight. Objective: The study intended to evaluate thyroid patients' knowledge gaps with respect to, cultural beliefs about, and attitudes towards the practice of yoga as a therapeutic tool in India. Design: The research team conducted a cross-sectional survey electronically using a snowball sampling technique. Setting: The study took place at Swami Vivekananda Yoga Anusandhana Samsthana (S-VYASA) Yoga University in Bengaluru, Karnataka, India. Participants: Participants were patients with thyroid dysfunction in India. Outcome Measures: The research team: (1) evaluated the overall awareness of, opinions about, and practice of yoga among participants, (2) correlated the findings with participants' sociodemographic characteristics, specific thyroid disease and comorbidities using the knowledge, attitude, and practice (KAP) model and Tableau analysis. Results: Among respondents, 192 patients were eligible to participate in the survey, out of which 31.8% were yoga practitioners and 68.2% weren't. All participants confirmed that they had heard the term yoga. The second group's awareness of yoga's use as a therapy was limited. Many nonpractitioners stated that they lacked knowledge of and feared injury from the practice of yoga, yet they showed interest in receiving yogic counseling. Of the 192 participants, 85.94% had received a clinical diagnosis of hypothyroidism, out of which 64% were female and 22% were male. The remaining 14% of participants had received other diagnosis along the spectrum of thyroid dysfunction. The prominent comorbidity was obesity at 28.13% among both genders, and in addition, 20.83% of females had polycystic ovarian syndrome. Conclusions: This study found an inadequate level of knowledge of yoga as a therapy among thyroid patients. Because yoga is progressive in improving endocrinal functions and is one of the complementary therapies for managing thyroid dysfunction, the research team recommends its integration into conventional medicine as an adjunct therapy. This study provides the scope for future studies about yoga and thyroid dysfunction among a wide range of age groups across the globe.
Asunto(s)
Enfermedades de la Tiroides , Yoga , Humanos , Masculino , Femenino , Yoga/psicología , Estudios Transversales , Conocimientos, Actitudes y Práctica en Salud , India , Enfermedades de la Tiroides/terapiaRESUMEN
INTRODUCTION: Thyroid diseases are common in women in their late reproductive years; therefore, thyroid disease and menopause may co-exist. Both conditions may present with a wide range of symptoms, leading to diagnostic challenges and delayed diagnosis. Aim To construct the first European Menopause and Andropause Society (EMAS) statement on thyroid diseases and menopause. MATERIALS AND METHODS: Literature review and consensus of expert opinion (EMAS executive board members/experts on menopause and thyroid disease). SUMMARY RECOMMENDATIONS: This position paper highlights the diagnostic and therapeutic dilemmas in managing women with thyroid disease during the menopausal transition, aiming to increase healthcare professionals' awareness of thyroid disorders and menopause-related symptoms. Clinical decisions regarding the treatment of both conditions should be made with caution and attention to the specific characteristics of this age group while adopting a personalized patient approach. The latter must include the family history, involvement of the woman in the decision-making, and respect for her preferences, to achieve overall well-being.
Asunto(s)
Menopausia , Enfermedades de la Tiroides , Femenino , Humanos , Enfermedades de la Tiroides/terapia , Enfermedades de la Tiroides/diagnósticoRESUMEN
Background: It has been reported that intracytoplasmic sperm injection (ICSI) may be the preferred fertilization method for women with thyroid autoimmunity (TAI) seeking assisted reproduction. We compared the reproductive outcomes of women with TAI who were treated with ICSI compared with in vitro fertilization (IVF). Methods: In this retrospective cohort study, we included women with infertility who were referred to the Reproductive Centre of Peking University Third Hospital for their first IVF/ICSI and embryo transfer (ET) treatment cycle from January 2019 to February 2021. In total, 2171 and 743 women with TAI underwent IVF and ICSI, respectively, while 8702 and 2668 women without TAI underwent IVF and ICSI, respectively. We examined the cumulative live birth rate (primary outcome) from the initiated stimulative cycle as well as the secondary outcomes of fertilization rate, rates of clinical pregnancy, and live birth after the first ET cycle. We compared the reproductive outcomes of women treated with IVF and ICSI according to TAI status. Multivariable logistic regression analyses were performed to adjust for relevant confounders. Results: Women who underwent ICSI had significantly higher fertilization rates than those who underwent IVF (median [interquartile range]: 0.6 [0.5-0.8] in the TAI-positive and IVF group vs. 0.7 [0.5-0.8] in the TAI-positive and ICSI group vs. 0.6 [0.5-0.8] the TAI-negative and IVF group vs. 0.7 [0.5-0.8] in the TAI-negative and ICSI group, p < 0.001). However, the rates of cumulative live births, clinical pregnancies, and live births were significantly lower among women with TAI who underwent ICSI than those who underwent IVF (cumulative live birth: 51.8% vs. 47%, adjusted odds ratio [aOR]: 0.80 [confidence interval, CI: 0.67-0.97]; clinical pregnancy: 43.0% vs. 38.8%, aOR: 0.81 [CI: 0.67-0.97]; live birth: 36.2% vs. 32.4%, aOR: 0.81 [CI: 0.66-0.98]). Conclusion: We observed that the use of ICSI in women with TAI was not associated with better assisted reproductive outcomes compared with IVF. Further prospective clinical trials are needed to confirm our findings.
Asunto(s)
Autoinmunidad , Fertilización In Vitro , Infertilidad Femenina , Índice de Embarazo , Inyecciones de Esperma Intracitoplasmáticas , Humanos , Femenino , Adulto , Fertilización In Vitro/métodos , Embarazo , Infertilidad Femenina/terapia , Infertilidad Femenina/inmunología , Estudios Retrospectivos , Nacimiento Vivo , Enfermedades de la Tiroides/inmunología , Enfermedades de la Tiroides/terapia , Enfermedades de la Tiroides/complicaciones , Glándula Tiroides/inmunologíaRESUMEN
Impaired sensitivity to thyroid hormones encompasses disorders with defective transport of hormones into cells, reduced hormone metabolism, and resistance to hormone action. Mediated by heritable single-gene defects, these rare conditions exhibit different patterns of discordant thyroid function associated with multisystem phenotypes. In this context, challenges include ruling out other causes of biochemical discordance, making a diagnosis using clinical features together with the identification of pathogenic variants in causal genes, and managing these rare disorders with a limited evidence base. For each condition, the present guidelines aim to inform clinical practice by summarizing key clinical features and useful investigations, criteria for molecular genetic diagnosis, and pathways for management and therapy. Specific, key recommendations were developed by combining the best research evidence available with the knowledge and clinical experience of panel members, to achieve a consensus.
Asunto(s)
Hormonas Tiroideas , Humanos , Hormonas Tiroideas/sangre , Hormonas Tiroideas/metabolismo , Europa (Continente) , Enfermedades de la Tiroides/genética , Enfermedades de la Tiroides/terapia , Enfermedades de la Tiroides/diagnóstico , Enfermedades de la Tiroides/metabolismo , Sociedades Médicas , Síndrome de Resistencia a Hormonas Tiroideas/genética , Síndrome de Resistencia a Hormonas Tiroideas/diagnóstico , Síndrome de Resistencia a Hormonas Tiroideas/terapiaRESUMEN
Heart failure is hemodynamically characterized as congestion and/or end-organ hypoperfusion, and is associated with increased morbidity and mortality. Underlying pathophysiology, such as neuro-hormonal activation, exacerbates heart failure and leads to functional deterioration of other organs. We have been conducting clinical research to study the pathophysiology of heart failure and discover prognostic factors. In this review article, we report the results and implications of our clinical research on heart failure.
Asunto(s)
Insuficiencia Cardíaca , Humanos , Insuficiencia Cardíaca/fisiopatología , Insuficiencia Cardíaca/terapia , Insuficiencia Cardíaca/etiología , Enfermedades Renales/etiología , Enfermedades Renales/terapia , Enfermedades Renales/fisiopatología , Enfermedades de la Tiroides/terapia , Enfermedades de la Tiroides/complicaciones , Hepatopatías/terapia , Hepatopatías/etiología , Hepatopatías/fisiopatologíaRESUMEN
This article includes a review of information primary care physicians need to know direct their evaluation and treatment of thyroid disorders that include sick euthyroid, hyperthyroidism, hypothyroidism, and subclinical thyroid disorders.
Asunto(s)
Atención Primaria de Salud , Enfermedades de la Tiroides , Humanos , Enfermedades de la Tiroides/diagnóstico , Enfermedades de la Tiroides/terapia , Atención Primaria de Salud/organización & administración , Hipertiroidismo/diagnóstico , Hipertiroidismo/terapia , Hipotiroidismo/diagnóstico , Hipotiroidismo/terapia , Hipotiroidismo/tratamiento farmacológico , Pruebas de Función de la TiroidesRESUMEN
BACKGROUND: This real-world analysis aimed at characterizing patients hospitalized for alopecia areata (AA) in Italy, focusing on comorbidities, treatment patterns and the economic burden for disease management. METHODS: Administrative databases of healthcare entities covering 8.9 million residents were retrospectively browsed to include patients of all ages with hospitalization discharge diagnosis for AA from 2010 to 2020. The population was characterized during the year before the first AA-related hospitalization (index-date) and followed-up for all the available successive period. AA drug prescriptions and treatment discontinuation were analyzed during follow-up. Healthcare costs were also examined. RESULTS: Among 252 patients with AA (mean age 32.1 years, 40.9% males), the most common comorbidities were thyroid disease (22.2%) and hypertension (21.8%), consistent with literature; only 44.4% (112/252) received therapy for AA, more frequently with prednisone, triamcinolone and clobetasol. Treatment discontinuation (no prescriptions during the last trimester) was observed in 86% and 88% of patients, respectively at 12 and 24-month after therapy initiation. Overall healthcare costs were 1715 per patient (rising to 2143 in the presence of comorbidities), mostly driven by hospitalization and drugs expenses. CONCLUSIONS: This first real-world description of hospitalized AA patients in Italy confirmed the youth and female predominance of this population, in line with international data. The large use of corticosteroids over other systemic therapies followed the Italian guidelines, but the high discontinuation rates suggest an unmet need for further treatment options. Lastly, the analysis of healthcare expenses indicated that hospitalizations and drugs were the most impactive cost items.
Asunto(s)
Alopecia Areata , Hospitalización , Humanos , Italia/epidemiología , Alopecia Areata/epidemiología , Alopecia Areata/economía , Alopecia Areata/terapia , Masculino , Femenino , Adulto , Estudios Retrospectivos , Hospitalización/economía , Hospitalización/estadística & datos numéricos , Adolescente , Adulto Joven , Persona de Mediana Edad , Niño , Costos de la Atención en Salud/estadística & datos numéricos , Comorbilidad , Preescolar , Enfermedades de la Tiroides/epidemiología , Enfermedades de la Tiroides/economía , Enfermedades de la Tiroides/terapia , Hipertensión/epidemiología , Hipertensión/tratamiento farmacológico , Hipertensión/economía , AncianoAsunto(s)
Enfermedad de Graves , Complicaciones del Embarazo , Humanos , Enfermedad de Graves/diagnóstico , Femenino , Embarazo , Recién Nacido , Complicaciones del Embarazo/diagnóstico , Complicaciones del Embarazo/terapia , Enfermedades de la Tiroides/diagnóstico , Enfermedades de la Tiroides/terapiaRESUMEN
ABSTRACT Objective: Choosing Wisely (CW) is an initiative that aims to advance the dialogue between physicians and patients about low-value health interventions. Given that thyroid conditions are frequent in clinical practice, we aimed to develop an evidence-based list of thyroid CW recommendations. Materials and methods: The Thyroid Department of the Brazilian Society of Endocrinology and Metabolism (SBEM) named a Task Force to conduct the initiative. The Task Force work was based on an electronic Delphi approach. The 10 recommendations that received the highest scores by the Task Force were submitted for voting by all SBEM associates. The 5 recommendations that received the highest scores by SBEM associates are presented herein. Results: The Task Force was composed of 14 thyroidologists from 10 tertiary-care, teaching-based Brazilian institutions. The brainstorming/ideation phase resulted in 69 recommendations. After the removal of duplicates and recommendations that did not adhere to the initiative's scope, 35 remained. Then the Task Force voted to attribute a grade (0 [lowest agreement] to 10 [highest agreement]) for each recommendation. The 10 recommendations that received the highest scores by the Task Force were submitted to all SBEM associates. A total of 683 associates voted electronically, attributing a grade (0 to 10) for each recommendation. The 5 recommendations that received the highest scores by the SBEM associates compose our final list. Conclusion: A set of recommendations to avoid unnecessary medical tests, treatments, or procedures for thyroid conditions are offered with a transparent methodology. This initiative aims to foster productive interactions between physicians and patients, stimulating shared decision-making.
Asunto(s)
Humanos , Enfermedades de la Tiroides/diagnóstico , Enfermedades de la Tiroides/terapia , Glándula Tiroides , Endocrinología , Sociedades Médicas , BrasilRESUMEN
Introducción: La diabetes mellitus tipo 1 es una enfermedad autoinmunitaria que se relaciona con alteraciones tiroideas. Objetivo: Describir la relación que existe entre diabetes mellitus tipo 1 y enfermedad tiroidea autoinmune. Métodos: Se realizó una revisión de la literatura nacional e internacional de los últimos 15 años en bases de datos, en español y en inglés. Se utilizaron las siguientes palabras clave: diabetes mellitus tipo 1, autoinmunidad, enfermad tiroidea autoinmune, disfunción tiroidea y anticuerpos antitiroideos. Análisis e integración de la información: La alteración más frecuente es el hipotiroidismo subclínico y se presenta con mayor frecuencia en el sexo femenino, por lo que se sugiere realizar periódicamente el perfil tiroideo a estos pacientes. Conclusiones: Se debe tener en cuenta en la práctica clínica estas implicaciones para brindar un tratamiento oportuno, mejorar complicaciones derivadas como las enfermedades cardiovasculares y disminuir las cifras de morbilidad y mortalidad(AU)
Introduction: Type 1 diabetes mellitus is an autoimmune disease that is related to thyroid abnormalities. Objective: Describe the relationship between type 1 diabetes mellitus and autoimmune thyroid disease. Methods: A review of the national and international literature of the last 15 years was carried out in databases, in Spanish and in English. The following keywords were used: type 1 diabetes mellitus, autoimmune, autoimmune thyroid disease, thyroid dysfunction and antithyroid antibodies. Analysis and integration of information: The most common alteration is subclinical hypothyroidism and it occurs most often in the female sex, so it is suggested to periodically perform the thyroid profile to these patients. Conclusions: These implications should be taken into account in clinical practice to provide timely treatment, improve complications such as cardiovascular disease and reduce morbidity and mortality figures(AU)
Asunto(s)
Humanos , Enfermedades de la Tiroides/terapia , Tiroiditis Autoinmune , Diabetes Mellitus Tipo 1/etiología , Literatura de Revisión como AsuntoRESUMEN
ABSTRACT This position statement was prepared to guide endocrinologists on the best approach to managing thyroid disorders during the coronavirus disease (COVID-19) pandemic. The most frequent thyroid hormonal findings in patients with COVID-19, particularly in individuals with severe disease, are similar to those present in the non-thyroidal illness syndrome and require no intervention. Subacute thyroiditis has also been reported during COVID-19 infection. Diagnosis and treatment of hypothyroidism during the COVID-19 pandemic may follow usual practice; however, should avoid frequent laboratory tests in patients with previous controlled disease. Well-controlled hypo and hyperthyroidism are not associated with an increased risk of COVID-19 infection or severity. Newly diagnosed hyperthyroidism during the pandemic should be preferably treated with antithyroid drugs (ATDs), bearing in mind the possibility of rare side effects with these medications, particularly agranulocytosis, which requires immediate intervention. Definitive treatment of hyperthyroidism (radioiodine therapy or surgery) may be considered in those cases that protective protocols can be followed to avoid COVID-19 contamination or once the pandemic is over. In patients with moderate Graves' ophthalmopathy (GO) not at risk of visual loss, glucocorticoids at immunosuppressive doses should be avoided, while in those with severe GO without COVID-19 and at risk of vision loss, intravenous glucocorticoid is the therapeutic choice. Considering that most of the thyroid cancer cases are low risk and associated with an excellent prognosis, surgical procedures could and should be postponed safely during the pandemic period. Additionally, when indicated, radioiodine therapy could also be safely postponed as long as it is possible.
Asunto(s)
Humanos , Enfermedades de la Tiroides/terapia , COVID-19 , Glándula Tiroides , Brasil , Oftalmopatía de Graves/terapia , Pandemias , Hipertiroidismo/terapia , Radioisótopos de YodoRESUMEN
Background: Atrial fibrillation (AF) has the close relation to thyroid dysfunction and these two diseases lead to poor cardiovascular outcomes. But the prognostic value of thyroid diseases in AF remains unclear. We aimed to determine whether history of thyroid diseases is associated with risk of in-hospital cardiovascular outcomes in AF.MethodsBased on the data from the CCC-AF (Improving Care for Cardiovascular Diseases in China-Atrial Fibrillation) project, 31,486 inpatients with a definitive diagnosis of AF and record of history of thyroid diseases were included. Logistic regression analysis was performed to investigate the relationship between history of thyroid diseases and risk of in-hospital major adverse cardiovascular events (MACE) in AF.ResultsAmong AF patients, 503 (1.6%) had a history of hypothyroidism, 642 (2.0%) had a history of hyperthyroidism and 30,341 (96.4%) had no thyroid dysfunction. During this hospitalization, 5146 (16.3%) AF patients suffered from MACE. The incidence was 13.1% in hypothyroidism, 16.3% in euthyroidism and 19.0% in hyperthyroidism, in which there was a significant difference among three groups (p=0.028). Multivariable logistic regression analysis revealed that history of hypothyroidism decreased but history of hyperthyroidism increased the risk of in-hospital MACE in AF patients (adjusted odds ratio [OR]=0.603; 95% confidence interval [CI], 0.4490.811; p=0.001 versus adjusted OR=1.327; 95% CI, 1.0601.661; p=0.013).ConclusionHistory of hypothyroidism was an independent protective factor, whereas history of hyperthyroidism was an independent risk factor for in-hospital cardiovascular outcomes in AF. Our study indicated that hyperthyroidism should be treated aggressively in order to improve the prognosis of AF. (AU)
Antecedentes: La fibrilación auricular (FA) está estrechamente relacionada con la disfunción tiroidea, y estas 2 enfermedades conducen a resultados cardiovasculares deficientes. Pero el valor pronóstico de las enfermedades tiroideas en la FA sigue sin estar claro. Nuestro objetivo era determinar si la historia de enfermedades tiroideas está asociada con el riesgo de resultados cardiovasculares intrahospitalarios en la FA.MétodosEn base a los datos del proyecto de mejora de la atención de las enfermedades cardiovasculares en China - fibrilación auricular (CCC-FA, por sus siglas en inglés), se incluyeron 31.486 pacientes hospitalizados con un diagnóstico definitivo de FA y un registro de antecedentes de enfermedades tiroideas. Se realizó un análisis de regresión logística para investigar la relación entre la historia de las enfermedades tiroideas y el riesgo de eventos cardiovasculares adversos importantes intrahospitalarios (MACE) en FA.ResultadosEntre los pacientes con FA, 503 (1,6%) tenían antecedentes de hipotiroidismo, 642 (2,0%) antecedentes de hipertiroidismo y 30.341 (96,4%) no tenía disfunción tiroidea. Durante esta hospitalización, 5.146 (16,3%) pacientes con FA sufrieron de MACE. La incidencia fue del 13,1% en hipotiroidismo, del 16,3% en eutiroidismo y del 19,0% en hipertiroidismo, en los que hubo una diferencia significativa entre 3 grupos (p=0,028). El análisis de regresión logística multivariable reveló que la historia de hipotiroidismo disminuyó, pero la historia de hipertiroidismo aumentó el riesgo de MACE intrahospitalario en pacientes con FA (relación de probabilidades ajustadas [OR]: 0,603; intervalo de confianza [IC] del 95%: 0,449-0,811; p=0,001 frente a OR ajustado 1,327; IC del 95%: 1,060-1,661; p=0,013). (AU)
Asunto(s)
Humanos , Fibrilación Atrial/complicaciones , Fibrilación Atrial/etiología , Fibrilación Atrial/terapia , Enfermedades Cardiovasculares/epidemiología , Enfermedades Cardiovasculares/etiología , Enfermedades Cardiovasculares/terapia , Mejoramiento de la Calidad , Factores de Riesgo , China/epidemiología , Hospitales , Enfermedades de la Tiroides/complicaciones , Enfermedades de la Tiroides/epidemiología , Enfermedades de la Tiroides/terapiaRESUMEN
INTRODUCCIÓN Y OBJETIVO: El tratamiento de la patología con radioyodo (RAI) se viene realizando desde hace más de 7 décadas. Sin embargo, no existe consenso en cuanto a indicaciones, dosis y otros aspectos relacionados con el cuidado de los pacientes. La razón de ello es la ausencia de ensayos clínicos prospectivos bien diseñadospara resolver estos interrogantes en cuanto al tratamiento con 131I, a pesar de la alta prevalencia de las enfermedades tiroideas. El tratamiento con 131I está indicado en el tratamiento del hipertiroidismo, producido por la enfermedad de Graves, por el adenoma tóxico y por el bocio multinodular tóxico; del bocio multinodular no tóxico y del carcinoma diferenciado de tiroides (CDT). El objetivo del tratamiento con RAI en caso del hipertiroidismo y del bocio multinodular no tóxico es disminuir la función tiroidea o disminuir el volumen de la glándula tiroides. En el caso del CDT, los objetivos de la administración de RAI tras la cirugía son la ablación de los restos tiroideos, el tratamiento adyuvante de la enfermedad microscópica sospechada no confirmada y el tratamiento de la enfermedad persistente loco-regional o metastásica. A la espera de los resultados de ensayos clínicos actualmente en: marcha, el tratamiento con 131I está justificado no solo en los pacientes de alto riesgo, sino también en los pacientes de riesgo bajo (T > 1 cm) e intermedio
Introduction and ojective: Radioiodine (RAI) therapy of the thyroid diseases has been used for seven decades. However, there is no consensus regarding indications, doses, procedures, and other aspects related to the clinical care of the patients considered for 131I therapy. The reason for this is the lack of large well-designed prospective clinical trials resolving fundamental questions in relation to 131I therapy, despite the high prevalence of thyroid diseases. Radioiodine therapy is indicated for the treatment of hyperthyroidism (Graves'disease, toxic nodular goiter and toxic multinodular goiter), multinodular nontoxic goiter and differentiated thyroid carcinoma (DTC). In benign thyroid diseases, RAI is administered to decrease the thyroid function and/or reduction of the thyroid volume. In DTC, post-operative administration of RAI may includeremnant ablation to eliminate residual normal thyroid tissue after thyroidectomy, adjuvant therapy to destroy suspected, but unproven residual disease and RAI therapy to treat persistent disease in higher risk patients. Pending the results of the prospective clinical trials that are currently underway, the use of 131I seems to be justified not only in high-risk patients, but also in low-intermediate-risk patients
Asunto(s)
Humanos , Enfermedades de la Tiroides/terapia , Glándula Tiroides/efectos de los fármacos , Radioisótopos de Yodo/uso terapéutico , Hipertiroidismo/terapia , Radioisótopos de Yodo/metabolismo , Neoplasias de la Tiroides/terapia , Liposarcoma/terapiaRESUMEN
La relación entre inmunidad y cáncer es compleja. Las células tumorales desarrollan mecanismos de evasión a las respuestas del sistema inmunitario. Esta capacidad permite su supervivencia y crecimiento. La inmunoterapia ha transformado el tratamiento oncológico mejorando la respuesta inmunitaria contra la célula tumoral. Esta se basa en el bloqueo de los puntos de control inmunitario mediante anticuerpos monoclonales contra la molécula inhibidora CTLA-4 (antígeno 4 del linfocito T citotóxico [CTLA-4]) y la proteína 1 de muerte celular programada y su ligando (PD-1/PD-L1). Aunque los inhibidores de los puntos de control inmunitario (ICIs) son fármacos bien tolerados, tienen un perfil de efectos adversos conocido como eventos adversos inmunorrelacionados (EAI). Estos afectan varios sistemas, incluyendo las glándulas endocrinas. Los eventos adversos endocrinos más frecuentes son la disfunción tiroidea, la insuficiencia hipofisaria, la diabetes mellitus autoinmune y la insuficiencia suprarrenal primaria. El creciente conocimiento de estos efectos adversos endocrinos ha llevado a estrategias de tratamiento efectivo con el reemplazo hormonal correspondiente. El objetivo de esta revisión es reconocer la incidencia de estas nuevas endocrinopatías, la fisiopatología, su valoración clínica y el manejo terapéutico. (AU)
The relationship between immunity and cancer is complex. Tumor cells develop evasion mechanisms to the immune system responses. This ability allows their survival and progression. Immunotherapy has transformed cancer treatment by improving the immune response against tumor cells. This is achieved by blocking immune checkpoints with monoclonal antibodies against cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and programmed cell death protein 1 and its ligand (PD-1 / PD-L1). Although the immune checkpoint inhibitors (ICIs) are well tolerated drugs, they have a profile of adverse effects known as immune-related adverse events (irAES). These involve diverse systems, including the endocrine glands. The most frequent endocrine immune-related adverse events are thyroid and pituitary dysfunction, autoimmune diabetes mellitus and primary adrenal insufficiency. The increasing knowledge of these irAES has led to effective treatment strategies with the corresponding hormonal replacement. The objective of this review is to recognize the incidence of these new endocrinopathies, the physiopathology, their clinical evaluation, and therapeutic management. (AU)
Asunto(s)
Humanos , Enfermedades del Sistema Endocrino/inducido químicamente , Inmunoterapia/efectos adversos , Enfermedades de la Tiroides/diagnóstico , Enfermedades de la Tiroides/inducido químicamente , Enfermedades de la Tiroides/patología , Enfermedades de la Tiroides/terapia , Tiroxina/administración & dosificación , Triyodotironina/uso terapéutico , Corticoesteroides/administración & dosificación , Insuficiencia Suprarrenal/diagnóstico , Insuficiencia Suprarrenal/inducido químicamente , Insuficiencia Suprarrenal/patología , Insuficiencia Suprarrenal/terapia , Diabetes Mellitus Tipo 1/diagnóstico , Diabetes Mellitus Tipo 1/inducido químicamente , Diabetes Mellitus Tipo 1/patología , Diabetes Mellitus Tipo 1/terapia , Enfermedades del Sistema Endocrino/diagnóstico , Enfermedades del Sistema Endocrino/fisiopatología , Enfermedades del Sistema Endocrino/terapia , Hipofisitis/diagnóstico , Hipofisitis/inducido químicamente , Hipofisitis/patología , Hipofisitis/terapia , Glucocorticoides/administración & dosificación , Insulina/uso terapéutico , Metimazol/uso terapéutico , Mineralocorticoides/uso terapéutico , Anticuerpos Monoclonales/uso terapéutico , Neoplasias/inmunologíaRESUMEN
Los trastornos de la función tiroidea afectan profundamente al sistema cardiovascular. En esta revisión se presentan algunos aspectos fisiológicos de la interrelación entre tiroides y corazón, como también las consecuencias de la tirotoxicosis e hipotiroidismo sobre el aparato cardiovascular. Se analiza la influencia del hipertiroidismo en la gèc)nesis de la fibrilación auricular y del hipotiroidismo en el metabolismo de las lipoproteínas. Adicionalmente, el artículo se referirá a los potenciales efectos adversos del antiarrítmico amiodarona sobre la función tiroidea y cómo se investigan y tratan. Finalmente, se expone un caso clínico real para ilustrar con mayor claridad la enorme importancia que pueden alcanzar las relaciones fisiopatológicas entre el corazón y las afecciones de esta glándula endocrina.
Disorders of thyroid function profoundly affect the cardiovascular system. Inthisreviewsomephysiologicalaspectsoftherelationship between thyroid and the heart as well as the consequences of thyrotoxicosis and hypothyroidism on the cardiovascular system are presented. The influence of hyperthyroidism is analyzed in the genesis of atrial fibrillation and of hypothyroidism on lipoprotein metabolism. Furthermore, we refer to the potential adverse effects of the antiarrhythmic amiodarone on thyroid function and how they are investigated and treated. Finally, a real clinical case is exposed to more clearly illustrate the enormous importance that can reach the pathophysiological relationships between the heart and the diseases of the thyroid gland.
Asunto(s)
Humanos , Enfermedades de la Tiroides/fisiopatología , Sistema Cardiovascular/fisiopatología , Sistema Cardiovascular/metabolismo , Fibrilación Atrial , Enfermedades de la Tiroides/inducido químicamente , Enfermedades de la Tiroides/metabolismo , Enfermedades de la Tiroides/terapia , Hormonas Tiroideas/metabolismo , Amiodarona/efectos adversos , Hipertiroidismo/fisiopatología , Hipotiroidismo/fisiopatología , AntiarrítmicosRESUMEN
Las enfermedades del tiroides (ET) siguen incrementando su frecuencia diagnóstica, y específicamente, la enfermedad nodular tiroidea, constituye una de las causas de mayor asistencia a consultas de Endocrinología. Un gran porcentaje de estas enfermedades, cursan de forma latente o subclínica, y en ocasiones, esto favorece que se desestime la importancia de algunas condiciones desfavorables que se presentan sobre: la tensión arterial, el ritmo cardiaco, la contractilidad cardiaca, la función diastólica, la aparición o incremento del estado de insulinorresistencia y las dislipidemias. A estas manifestaciones se suman también, factores de riesgo patogénicos asociados a las ET, que si no se identifican a tiempo y se corrigen de ser posible, pueden agravar o entorpecer su evolución y la respuesta al tratamiento (déficit de yodo, hierro y selenio, contaminación, estrés, adicción por el tabaquismo y la obesidad).1 En las formas clínicas manifiestas tiene gran valor la pesquisa de algunas consecuencias que cursan de forma asintomática, y que con un diagnóstico y tratamiento oportunos disminuyen la morbilidad asociada a estas enfermedades. Tal es el caso de la relación hipertiroidismo y osteoporosis en las mujeres peri y posmenopáusicas; y de los desórdenes por déficit de yodo, como una de las causas más frecuentes de bocio y de efectos deletéreos sobre la evolución adecuada de la gestación y el producto de la concepción...(AU)
Asunto(s)
Humanos , Enfermedades de la Tiroides/diagnóstico , Enfermedades de la Tiroides/terapia , Evaluación del Impacto en la Salud/tendenciasRESUMEN
Las enfermedades tiroideas son un importante problema de salud que afecta a un gran porcentaje de la población. Las pruebas bioquímicas constituyen el pilar fundamental para su diagnóstico y seguimiento. El desarrollo de ensayos de segunda y tercera generación ha supuesto un gran avance en el diagnóstico de estas enfermedades. El texto incluye los ensayos utilizados para diagnosticar y tratar las diferentes enfermedades tiroideas, provee información bioquímica y clínica actualizada contenida en secciones referidas a la utilidad clínica de las determinaciones de hormonas tiroideas totales y libres, anticuerpos antitiroideos, tirotropina humana y tiroglobulina, de manera que pueda ofrecer, tanto al laboratorio como al médico, un panorama general de la utilidad y la capacidad actual de estas pruebas(AU)
Thyroid diseases are a significant health problem affecting a high percentage of the population. The biochemical tests are the fundamental pillar for diagnosis and follow-up. The development of second and third-generation assays has represented a great advance in diagnosing these diseases. The text covers the tests to diagnose and treat a number of thyroid diseases, and provides the reader with updated biochemical and clinical information in sections about the clinical usefulness of total and free thyroid hormone determinations, antithyroid antibodies, human thyrotropin and thyroglobulin. In this way, it can offer both the lab and the physician a general overview of the usefulness and the current capability of these tests(AU)